-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $48

Benzinga·02/18/2026 17:34:11
Listen to the news
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $46 to $48.